Search Videos by Topic or Participant
Browse by Series:

Potential Immunotherapy Combinations in RCC

Discussant: Brian I. Rini, MD, Cleveland Clinic
Published: Tuesday, Jan 27, 2015
For High-Definition, Click
In addition to anti-PD-1 antibodies, those specifically targeted against PD-L1 have generated interest in renal cell carcinoma (RCC), notes Brian I. Rini, MD. The agent MPDL3280A has shown promise as a treatment for RCC and is now being explored with or without bevacizumab as an upfront treatment for patients with clear cell metastatic RCC.

The benefit of looking at bevacizumab is that it is not a TKI, notes Rini. This exciting study has accrued rapidly with an endpoint of progression-free survival.

Other combination studies are assessing pembrolizumab plus pazopanib; however, liver function abnormalities are a concern with this combination, Rini notes. Other studies are looking at anti-PD-1 agents with interferon, based on preclinical evidence of efficacy.

View the video, to hear the discussion.
Slider Left
Slider Right
For High-Definition, Click
In addition to anti-PD-1 antibodies, those specifically targeted against PD-L1 have generated interest in renal cell carcinoma (RCC), notes Brian I. Rini, MD. The agent MPDL3280A has shown promise as a treatment for RCC and is now being explored with or without bevacizumab as an upfront treatment for patients with clear cell metastatic RCC.

The benefit of looking at bevacizumab is that it is not a TKI, notes Rini. This exciting study has accrued rapidly with an endpoint of progression-free survival.

Other combination studies are assessing pembrolizumab plus pazopanib; however, liver function abnormalities are a concern with this combination, Rini notes. Other studies are looking at anti-PD-1 agents with interferon, based on preclinical evidence of efficacy.

View the video, to hear the discussion.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x